First subcutaneous anti-PD-1 cancer immunotherapy available to patients in Great Britain
Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to.
Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, today announced $41.5M in Series B funding co-led by Marshall .
Company to commercialize and create single-cell multi-omics products Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, today announced $41.5M in Series
Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to .